financetom
Business
financetom
/
Business
/
GE HealthCare Technologies' Q2 Adjusted Earnings, Revenue Rise
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
GE HealthCare Technologies' Q2 Adjusted Earnings, Revenue Rise
Jul 31, 2024 4:16 AM

06:46 AM EDT, 07/31/2024 (MT Newswires) -- GE HealthCare Technologies ( GEHC ) reported Q2 adjusted earnings Wednesday of $1 per diluted share, up from $0.92 a year earlier.

Analysts polled by Capital IQ expected $0.98.

Revenue for the quarter ended June 30 was $4.84 billion, compared with $4.82 billion a year earlier.

Analysts surveyed by Capital IQ expected $4.87 billion.

The company said it still expects full-year 2024 adjusted earnings of $4.20 to $4.35 per diluted share, but lowered its organic growth forecast to between 1% and 2% from 4% previously. Analysts polled by Capital IQ expect earnings of $4.27 on revenue of $20.12 billion.

The company's shares fell over 8% during recent pre-market activity on Wednesday.

Price: 76.20, Change: -6.45, Percent Change: -7.80

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Nissan may bring ultra-compact EV production in-house from 2028, sources say
Nissan may bring ultra-compact EV production in-house from 2028, sources say
Mar 8, 2024
By Maki Shiraki TOKYO (Reuters) - Japan's Nissan Motor ( NSANF ) may bring production of its ultra-compact electric vehicles in-house, five people familiar with the matter said, emboldened by the success of its Sakura model currently built by junior partner Mitsubishi Motors ( MMTOF ). The automaker is considering moving production to its factory on the southern island of...
Kyverna Therapeutics Teams Up With Stanford University to Evaluate Investigational Multiple Sclerosis Drug
Kyverna Therapeutics Teams Up With Stanford University to Evaluate Investigational Multiple Sclerosis Drug
Mar 8, 2024
05:20 AM EST, 03/08/2024 (MT Newswires) -- Kyverna Therapeutics ( KYTX ) said late Thursday it has formed a collaboration with Stanford University to allow the use the of the company's KYV-101 investigational therapy for multiple sclerosis in a phase 1 investigator-initiated trial. The trial will evaluate the safety, tolerability, and clinical activity of the drug in up to 12...
Compounded semaglutide poses serious U.S. health issue, Novo Nordisk CEO says
Compounded semaglutide poses serious U.S. health issue, Novo Nordisk CEO says
Mar 8, 2024
COPENHAGEN, March 8 (Reuters) - Novo Nordisk's CEO on Friday said compounded semaglutide in the United States is a serious health issue. ...
BYD spearheads Chinese electric car push in Australia, a friendlier market
BYD spearheads Chinese electric car push in Australia, a friendlier market
Mar 8, 2024
(This March 5 story has been corrected to attribute a prediction to BMI, a unit of Fitch Group, and not Fitch Ratings, in paragraph 25) By Stella Qiu SYDNEY (Reuters) - BYD and other Chinese automakers are bringing new electric car models in droves to Australia, a market where they haven't faced trade barriers and sales have surged due to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved